Literature DB >> 11346280

Hepatitis C among noninjecting drug users: a report.

S Tortu1, A Neaigus, J McMahon, D Hagen.   

Abstract

OBJECTIVES: This report documents the prevalence of hepatitis C virus (HCV) infection among self-reported noninjecting drug users recruited from two New York City neighborhoods.
METHODS: Participants were recruited in separate studies from East Harlem and the Lower East Side of Manhattan and were administered structured questionnaires and tested for HCV.
RESULTS: HCV prevalence rates among those reporting no history of injecting drugs ranged from 5% to 29%, according to age, gender, and study location.
CONCLUSIONS: Our results suggest that more research is needed to elucidate potential noninjecting routes of HCV transmission among drug users. Moreover, policies that rely predominantly on injector status as the only drug-related risk factor for HCV screening need to be reassessed in light of these findings.

Entities:  

Mesh:

Year:  2001        PMID: 11346280     DOI: 10.1081/ja-100102640

Source DB:  PubMed          Journal:  Subst Use Misuse        ISSN: 1082-6084            Impact factor:   2.164


  30 in total

1.  Molecular epidemiology of hepatitis C among drug users in Flanders, Belgium: association of genotype with clinical parameters and with sex- and drug-related risk behaviours.

Authors:  C Matheï; E Wollants; J Verbeeck; M Van Ranst; G Robaeys; P Van Damme; F Buntinx
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-08       Impact factor: 3.267

2.  Crack use as a public health problem in Canada: call for an evaluation of 'safer crack use kits'.

Authors:  Emma Haydon; Benedikt Fischer
Journal:  Can J Public Health       Date:  2005 May-Jun

Review 3.  Non-injection drug use and Hepatitis C Virus: a systematic review.

Authors:  Roberta Scheinmann; Holly Hagan; Corina Lelutiu-Weinberger; Rebecca Stern; Don C Des Jarlais; Peter L Flom; Shiela Strauss
Journal:  Drug Alcohol Depend       Date:  2006-12-15       Impact factor: 4.492

4.  Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States.

Authors:  Edmund J Bini; Steven Kritz; Lawrence S Brown; Jim Robinson; Donald Calsyn; Don Alderson; Kathlene Tracy; Patrick McAuliffe; Cheryl Smith; John Rotrosen
Journal:  J Subst Abuse Treat       Date:  2011-10-27

5.  Effectiveness of a risk screener in identifying hepatitis C virus in a primary care setting.

Authors:  Mari-Lynn Drainoni; Alain H Litwin; Bryce D Smith; Elisa A Koppelman; M Diane McKee; Cindy L Christiansen; Allen L Gifford; Cindy M Weinbaum; William N Southern
Journal:  Am J Public Health       Date:  2012-09-20       Impact factor: 9.308

6.  Do crack smoking practices change with the introduction of safer crack kits?

Authors:  Leslie A Malchy; Vicky Bungay; Joy L Johnson; Jane Buxton
Journal:  Can J Public Health       Date:  2011 May-Jun

7.  The association between use of non-injection drug implements and hepatitis C virus antibody status in homeless and marginally housed persons in San Francisco.

Authors:  Keith A Hermanstyne; David R Bangsberg; Karen Hennessey; Cindy Weinbaum; Judith A Hahn
Journal:  J Public Health (Oxf)       Date:  2012-03-26       Impact factor: 2.341

8.  Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada.

Authors:  Benedikt Fischer; Emma Haydon; Jürgen Rehm; Mel Krajden; Jens Reimer
Journal:  J Urban Health       Date:  2004-09       Impact factor: 3.671

9.  Intranasal transmission of hepatitis C virus: virological and clinical evidence.

Authors:  Sagiv Aaron; James M McMahon; Danielle Milano; Leilani Torres; Michael Clatts; Stephanie Tortu; Donna Mildvan; Malgorzata Simm
Journal:  Clin Infect Dis       Date:  2008-10-01       Impact factor: 9.079

10.  Fumando la piedra: emerging patterns of crack use among Latino immigrant day laborers in New Orleans.

Authors:  Avelardo Valdez; Alice Cepeda; Nalini Junko Negi; Charles Kaplan
Journal:  J Immigr Minor Health       Date:  2010-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.